TrialThe New England journal of medicine2016
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1,540 papers cite itlatest 60 shown
this paperpooled ittrialcites it